Wellgistics Health Explores Potential Acquisition of Neuritek Therapeutics

Wellgistics Health, Inc. has announced a non-exclusive, non-binding Letter of Intent to assess the potential acquisition of Neuritek Therapeutics, Inc., a neuroscience research organization. Valued at $105 million, the proposed all-stock transaction aims to enhance Wellgistics' healthcare platform by integrating research capabilities.

The acquisition would potentially strengthen Wellgistics' alignment in drug development and commercialization, improving pharmaceutical partnerships and pipeline visibility. It could also support revenue opportunities and enhance shareholder value through a more integrated approach.

However, the completion of this transaction depends on due diligence, negotiations, board approvals, and other closing conditions. The agreement is non-binding, leaving open the possibility of changes or the deal not materializing.

Beyond this evaluation, Wellgistics is exploring other strategic opportunities within the healthcare sector to pursue its growth objectives. Yet, there are no guarantees these efforts will lead to final deals.